Ocugen Taps Europe Chief as MENA Licensing Deal Sets Up a Three-Way Phase 3 Bet
Published on 10/15/2026 at 12:21 | Editorial boerse-global.de
Ocugen is staffing up on one continent and cashing in on another, a twin move that tells investors the US biotech intends to sell its gene therapies well before it has proof they work.
Jolanda Crombach was named General Manager of the company's Amsterdam-based European unit on October 6. Her brief covers the groundwork for planned marketing authorization filings, the Phase 3 development of OCU410, and the eventual commercial rollout of the preparations across Europe. Standing up a dedicated operating structure in the Netherlands signals that Ocugen wants to open core regions beyond its American home market on its own terms.
Roots Deal Opens MENA, With Milestones Tied to Sales
While Europe takes shape, the company locked in fresh financial and operational backing for its gene candidate OCU400 through an exclusive licensing agreement with Roots Pharmaceutical and strategic partner Al-Dhow International Holding. The pact covers the Middle East and North Africa.
Ocugen collects an upfront payment plus initial development payments of as much as $4 million. Should the agreed sales targets be met, milestone payments of up to $255 million come into play. On top of that, the parties set royalties of 22% on net sales. Manufacturing and supply of the product stay with Ocugen — a detail that leaves the company with a second revenue channel alongside the milestone structure.
Three Candidates in Late-Stage Testing, Data Still Years Out
The fundamental driver remains the clinical readout, and none of it is in hand yet. All three lead programs are in Phase 3: OCU400 against retinitis pigmentosa, OCU410 against geographic atrophy, and OCU410ST against Stargardt disease. Topline results for OCU400 are expected in the first quarter of 2027, with filings in the US and Europe to follow. Study results for the other two candidates are slated for 2027 and 2028.
Should investors sell immediately? Or is it worth buying Ocugen?
That timeline frames the central question for the market: will the science clear regulatory hurdles and unlock the milestone and royalty arrangements? Until the data land, every candidate stays investigational. Distribution networks in Europe or a MENA license generate little durable revenue without an approved product, and the gap until the first usable Phase 3 results demands patience and a tolerance for risk.
Management's case for the region rests on its assessment that retinitis pigmentosa prevalence in MENA runs ten to twenty times higher than in the United States or the European Union. Convincing topline data in early 2027 could set off a swift approval process in the target markets. If Amsterdam's commercial architecture is ready in parallel, Ocugen would be positioned to serve Europe without meaningful delay — and the three Phase 3 candidates would validate one another, casting the company as a diversified ophthalmology gene therapy player.
Dilution Risk Sits on the Other Side of the Trade
A substantial risk shadows that picture. Phase 3 gene therapy trials carry a significant probability of failure. Should OCU400 miss its primary endpoint in the first quarter of 2027, or should unexpected safety concerns surface, the planned US and European filings would fall away — and the $255 million in potential MENA milestones would be out of reach.
The financial load compounds the problem. Building a Dutch subsidiary while running three Phase 3 trials in parallel generates considerable ongoing costs, and meaningful revenue is unlikely before 2027. Delayed progress would raise the odds of a greater capital need, potentially covered through capital measures — a serious dilution risk for existing shareholders. The organizational expansion, in other words, heightens vulnerability if the clinical bet sours.
A Capital Vote Lands October 26
Shareholders also hold the company's future financing flexibility in their hands. Ocugen has once again postponed its extraordinary shareholder meeting on approving 250 million additional common shares. The rescheduled meeting is set for October 26, 2026, at 8:00 a.m. ET. The planned increase in share count is a prerequisite for securing future research and approval programs, which is why investors are watching the vote closely.
On the chart, the stock sat 10% above Wednesday's 52-week low of EUR 0.7050, a precarious position. Holding that floor suggests the market is pricing in a chance of step-by-step execution; a slide below it would signal that skepticism over the long wait for data and the associated financing costs has taken over. Shares changed hands at EUR 0.7620 today, up 1.3%, though they remain down 39% year to date. The pre-market quote stood at EUR 0.7770, with a market capitalization of EUR 298.05 million.
Near-term, the recruitment and study progress of the Phase 3 programs is the next tangible catalyst, ahead of the OCU400 topline readout in the first quarter of 2027 that will settle the question of approvability.
Ad
Ocugen Stock: New Analysis - 15 October
Fresh Ocugen information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
